Clinical trials: Disease;Neurological
Insomnia Disorder
A Study of HS-10506 in Chinese Patients With Insomnia Disorder
The primary purpose of this phase 3 study is to evaluate the safety and the efficacy of HS-10506 (change versus placebo) on latency to persistent sleep (LPS) and wakefulness after sleep onset (WASO) measured by polysomnography…
- Trial name
- NCT07587385
- Testing
- HS-10506
- Volunteers
- 732 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Cervicogenic Headache, Occipital Neuralgia
The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain
The purpose of this study is to learn if pain can be relieved by delivering small amounts of electricity (called "electrical stimulation") to the nerves at the top of the neck.
- Trial name
- NCT05491915
- Testing
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- SPR Therapeutics, Inc.
Alzheimer Disease
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
- Trial name
- NCT06427668
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Spinogenix
Hemiparesis
Post-stroke Motor Rehabilitation Using Functional Near-infrared Spectroscopy-based Brain-computer-interface
Chronic stroke survivors suffering from weaknesses or movement difficulties in their hand/arm are provided a system to aid in at-home rehabilitation for 6 weeks.
- Trial name
- fNIRS-PROMOTE (NCT05258591)
- Testing
- Axem Home
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Axem Neurotechnology Inc.
Duchenne Muscular Dystrophy
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy
This is a Phase 2 randomized, 2-period, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, efficacy, PK and PD of PF-06252616 administered to ambulatory boys diagnosed with Duchenne Muscular…
- Trial name
- NCT02310763
- Testing
- PF-06252616
- Where
- 66 sites in United States, Australia and 6 more
- Volunteers
- 121 people
- Sponsor
- Pfizer
Dyskinesia, Levodopa Induced Dyskinesia (LID)
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease
- Trial name
- EASE LID (NCT02136914)
- Testing
- ADS-5102
- Where
- 46 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Meningococcal Disease, Meningococcal Meningitis
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers…
- Trial name
- NCT01423084
- Testing
- Serogroup B meningococcal vaccine
- Where
- 13 sites in Australia, Canada
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Novartis
Ischemic Stroke, Systemic Embolism
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of…
- Trial name
- LeAAPS (NCT05478304)
- Testing
- AtriClip LAA Exclusion System
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 6,573 people
- Sponsor
- AtriCure, Inc.
Intracranial Aneurysms
Evaluation of a Novel Intrasaccular Embolization Device for the Treatment of Intracranial Aneurysms
The study is a prospective, multicenter single-arm cohort. The purpose of this study is to evaluate efficacy and safety of a novel intrasaccular embolization device for the treatment of intracranial aneurysms.
- Trial name
- NCT07022249
- Testing
- Intrasaccular Embolization Device
- Volunteers
- 150 people
- Sponsor
- Ton-Bridge Medical Tech. Co., Ltd
Inherited Mitochondrial Disease
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical…
- Trial name
- NCT05218655
- Testing
- Vatiquinone
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- PTC Therapeutics
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Diabetic Neuropathy
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
Phase 2/3 open-label trial to assess the safety and tolerability of long-term treatment with lacosamide (SPM 927) in subjects with painful diabetic neuropathy.
- Trial name
- NCT00235443
- Testing
- lacosamide
- Where
- 84 sites in United States
- Volunteers
- 451 people
- Sponsor
- UCB Pharma
Alzheimer's Disease
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00607308
- Testing
- PF-04360365
- Where
- 9 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Pfizer
Degenerative Disc Disease
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration.
- Trial name
- IDCT (NCT07254806)
- Testing
- IDCT (rebonuputemcel)
- Where
- 31 sites in United States
- Volunteers
- 162 people
- Sponsor
- DiscGenics, Inc.
Gastroparesis
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study.
- Trial name
- NCT01718938
- Testing
- velusetrag dose 1, velusetrag dose 2, velusetrag dose 3
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
Amyotrophic Lateral Sclerosis, Lou Gehrig Disease
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig Disease, Motor Neuron Disease, Motor Neuron Atrophy
- Trial name
- NCT06315608
- Testing
- MRG-001
- Volunteers
- 10 people
- Sponsor
- MedRegen LLC
Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1
Study of CAD-1883 for Spinocerebellar Ataxia
This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA).
- Conditions
- Spinocerebellar Ataxias, Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3
- Trial name
- Synchrony-1 (NCT04301284)
- Testing
- CAD-1883
- Where
- 6 sites in United States
- Sponsor
- Cadent Therapeutics
Multiple Sclerosis
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
This was a phase 2a study of MLN1202 to determine safety, tolerability and initial efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). It was conducted in 2 dose cohorts enrolling a total of 50 patients.
- Trial name
- NCT01199640
- Testing
- MLN1202
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hearing Loss, Sensorineural, Severe-to-profound Hearing Loss
Hearing and Structure Preservation Via ECochG
The goal of the study is to determine the benefit of using an ECochG-based corrective action guide during cochlear implant surgery compared to the traditional surgical approach without ECochG surveillance and guidance.
- Trial name
- PRESERVE (NCT06268340)
- Testing
- ECochG monitored CI surgery incl. corrective action guide, Routine CI surgery without ECochG monitoring
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 102 people
- Sponsor
- Advanced Bionics AG
Epilepsy
The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin
Multiple-dose, open-label, single-period study consisting of three consecutive phases
- Trial name
- NCT02287415
- Testing
- BIA 2-093, Warfarin
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.